JLJoseph M. Lyons

Joseph M. Lyons

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph M. Lyons has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Servaas Antonie Morré

    Institute for Public Health Genomics (IPHG), Department of Genetics and Cell Biology, Research School GROW (School for Oncology & Developmental Biology), Faculty of Health, Medicine & Life Sciences, University of Maastricht, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands

    3 shared publications
  • A Salvador Peña

    Immunogenetics, Department of Pathology, VU University Medical Centre, De Boelelaan 117, Amsterdam, Netherlands

    2 shared publications
  • James I. Ito

    Department of Infectious Diseases, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA 91010, USA

    2 shared publications
  • James Isami Ito

    Department of Infectious Diseases, City of Hope National Medical Center, Duarte, CA 91010, USA

    2 shared publications
  • Jr J I Ito

    Department of Infectious Diseases, City of Hope National Medical Center and Beckman Research Institute, Duarte, California 91010, USA

    2 shared publications
  • S A Morré

    Laboratory of Immunogenetics, Section of Immunogenetics of Infectious Diseases, VU University Medical Centre, Amsterdam 1081 BT, The Netherlands

    2 shared publications

Latest Publications

    • 1 November 2009
      • p. 15-23

    An integrated approach to Chlamydia trachomatis infection: the ICTI Consortium, an update.

    by J M Lyons, S Ouburg, S A Morré

    The desire for an integrated approach to the study of Chlamydia trachomatis infection of the female genital tract resulted in the creation of the "ICTI Consortium" (Integrated approach to the study of Chlamydia Trachomatis Infection) in 2005. The ICTI consortium is based on tight interaction and collaboration between basic scientists, clinicians, epidemiologists and health-care policy makers. This translational approach will help to further the valuable insight into the immunopathogenesis of this sexually transmitted infection in order to develop new intervention strategies, including the vaccines and screening programs necessary to effectively diagnose, treat and prevent C. trachomatis infection. This article provides an update of ICTI Consortium activities carried out until September 2009.


  • Open Access

    Do host genetic traits in the bacterial sensing system play a role in the development of Chlamydia trachomatis-associated tubal pathology in subfertile women?

    by Janneke E Den Hartog, Sander Ouburg, Jolande A Land, Joseph M Lyons, James I Ito, A Salvador Peña, Servaas A Morré

    In women, Chlamydia (C.) trachomatis upper genital tract infection can cause distal tubal damage and occlusion, increasing the risk of tubal factor subfertility and ectopic pregnancy. Variations, like single nucleotide polymorphisms (SNPs), in immunologically important host genes are assumed to play a role in the course and outcome of a C. trachomatis infection. We studied whether genetic traits (carrying multiple SNPs in different genes) in the bacterial sensing system are associated with an aberrant immune response and subsequently with tubal pathology following a C. trachomatis infection. The genes studied all encode for pattern recognition receptors (PRRs) involved in sensing bacterial components. Of 227 subfertile women, serum was available for C. trachomatis IgG antibody testing and genotyping (common versus rare allele) of the PRR genes TLR9, TLR4, CD14 and CARD15/NOD2. In all women, a laparoscopy was performed to assess the grade of tubal pathology. Tubal pathology was defined as extensive peri-adnexal adhesions and/or distal occlusion of at least one tube. Following a C. trachomatis infection (i.e. C. trachomatis IgG positive), subfertile women carrying two or more SNPs in C. trachomatis PRR genes were at increased risk of tubal pathology compared to women carrying less than two SNPs (73% vs 33% risk). The differences were not statistically significant (P = 0.15), but a trend was observed. Carrying multiple SNPs in C. trachomatis PRR genes tends to result in an aberrant immune response and a higher risk of tubal pathology following a C. trachomatis infection. Larger studies are needed to confirm our preliminary findings.


    • 1 March 2006
      • p. 83-97

    An integrated approach to the study of Chlamydia trachomatis infection of the female genital tract.

    by J M Lyons

    The two major aims of this thesis were firstly, to provide a basis for an integrated approach to study the oculogenital biovar of Chlamydia trachomatis in order to explain the complex and varied course of female genital tract infection; and secondly, to use the understanding gained through this approach to suggest possible intervention strategies. To accomplish this end, the projects conducted and reported upon in the thesis fall into four categorical sections. Part I of the thesis addresses the bacterial factors that contribute to the pathogenesis of infection using both in vitro observations and an in vivo experimental murine model. In Part II, host immunogenetic factors are analyzed using gene knockout mice and single nucleotide polymorphism (SNP) analysis of human genes. In Part III, the efficacy of prophylactic intervention on the susceptibility and course of female genital tract infection with C. trachomatis in the mouse is evaluated. Finally, in Part IV, the natural immune response to the pathogen and the relationship that these responses have on conferring protection and/or contributing to the pathology of disease are investigated to bring us closer to the ultimate protective intervention strategy: a vaccine against C. trachomatis. This article summarizes the aims and results of the thesis, followed by a general discussion and conclusions.


  • Open Access

    Efficacy of an Immune Modulator in Experimental Chlamydia trachomatis Infection of the Female Genital Tract

    by Joseph M. Lyons, James I. Ito, Servaas A. Morré

    Objective. The aim of this study was to determine if vaginal application of the immune response modifier imiquimod (Aldara cream, 3M Pharmaceuticals, St Paul, Minn) would alter the course and/or outcome of female genital tract infection with a human isolate of Chlamydia trachomatis in a murine model. Methods. Groups of CF-1 mice were treated with Aldara on three different schedules: (1) ongoing beginning 5 days prior to and continuing through day 5 of infection; (2) a single prophylactic dose 2 hours prior to infection; and (3) therapeutic from day 4 to day 14 of infection. Mice were infected vaginally with a serovar D strain of C trachomatis, and monitored by culture to determine the level of shedding and duration of infection. Results. We observed a significant reduction in both duration of infection and the level of shedding during the acute phase in mice treated on an ongoing basis commencing 5 days prior to infection. There was no effect with respect to the other regimens. Conclusion. These results demonstrate that ongoing Aldara treatment has efficacy and may enhance local innate immunity which reduces the duration of subsequent infection with human isolates of C trachomatis in a murine model of female genital tract infection.


    • 1 December 2005
      • Vol. 38  (6) , 383-93

    Comparison of multiple genital tract infections with Chlamydia trachomatis in different strains of female mice.

    by Joseph M Lyons, Servaas A Morré, Lucy P Airo-Brown, Amado S Peña, James I Ito

    We have previously shown that female outbred CF-1 mice are susceptible to prolonged genital tract infection with the oculogenital serovars (D-K) of Chlamydia trachomatis, and that partial homotypic and heterotypic protection against reinfection is induced. To understand the possible role of inherent T-helper 1 (Th1)/Th2 polarity bias on both the course of infection and the level of acquired immunity induced by infection, 2 immunologically different and well-characterized inbred strains of mice, BALB/c and C57BL/6, were studied in this model. Groups of mice were inoculated intravaginally with C. trachomatis serovar D (Ct D) and monitored by culture to determine the duration of initial infection. Two months later, mice were reinfected, and monitored along with age- and condition-matched control groups. Plasma and vaginal secretions were collected for serologic analysis and specific delayed-type hypersensitivity was assessed by footpad swelling. Initial infection in C57BL/6 mice was comparable in duration to outbred CF-1 mice (median duration 42 versus 43.5 days), while BALB/c mice had a shorter median duration of initial infection (12 days). All strains had significantly shorter durations of infection following reinfection. BALB/c mice shed 4-10 times more inclusion-forming units (IFU) than both C57BL/6 and CF-1 mice on sample days during the first week of infection and all strains shed less IFU during reinfection. C57BL/6 and BALB/c mice had significantly lower anti-Ct D immunoglobulin G titers in both plasma and vaginal secretions than CF-1 mice following resolution of infection; the frequency of immunoglobulin A seropositive vaginal secretions was less in both inbred strains, being significantly less in the case of C57BL/6 mice. Qualitative analysis of the antigen specificity and isotype composition revealed differences among the mouse strains. All 3 strains had detectable levels of specific footpad swelling on day 14 of infection, whereas only BALB/c mice showed a significant response at 70 days post-infection. Significant differences between 2 strains of mice that differ in Th1/Th2 polarity bias were observed in: 1) the duration of infection; 2) the level of bacterial shedding during infection; and 3) the quantitative and qualitative cellular and humoral responses made in response to female genital tract infection with a human oculogenital isolate of C. trachomatis. In addition, a similar and significant level of partial acquired immunity to reinfection was observed in both strains, suggesting that inherent Th1/Th2 polarity bias present upon initial infection does not prevent the development of a protective immune response within the genital tract during infection with an oculogenital isolate of C. trachomatis.


  • Open Access

    Acquired homotypic and heterotypic immunity against oculogenital Chlamydia trachomatis serovars following female genital tract infection in mice

    by Joseph M Lyons, Servaas A Morré, Lucy P Airo-Brown, A Salvador Peña, James I Ito

    Background: Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen causing female genital tract infection throughout the world. Reinfection with the same serovar, as well as multiple infections with different serovars, occurs in humans. Using a murine model of female C. trachomatis genital tract infection, we determined if homotypic and/or heterotypic protection against reinfection was induced following infection with human oculogenital strains of C. trachomatis belonging to two serovars (D and H) that have been shown to vary significantly in the course of infection in the murine model. Methods: Groups of outbred CF-1 mice were reinfected intravaginally with a strain of either serovar D or H, two months after initial infection with these strains. Cellular immune and serologic status, both quantitative and qualitative, was assessed following initial infection, and the course of infection was monitored by culturing vaginal samples collected every 2–7 days following reinfection. Results: Serovar D was both more virulent (longer duration of infection) and immunogenic (higher level of circulating and vaginal IgG and higher incidence of IgA in vaginal secretions) in the mouse genital tract. Although both serovars induced cross-reacting antibodies during the course of primary infection, prior infection with serovar H resulted in only a slight reduction in the median duration of infection against homotypic reinfection (p ~ 0.10), while prior infection with serovar D resulted in significant reduction in the median duration of infection against both homotypic (p < 0.01) and heterotypic reinfection (p < 0.01) when compared to primary infection in age and conditions matched controls. Conclusion: Serovar D infection resulted in significant homotypic and heterotypic protection against reinfection, while primary infection with serovar H resulted in only slight homotypic protection. In addition to being the first demonstration of acquired heterotypic immunity between human oculogenital serovars, the differences in the level and extent of this immunity could in part explain the stable difference in serovar prevalence among human isolates.


  • Open Access

    Differences in growth characteristics and elementary body associated cytotoxicity between Chlamydia trachomatis oculogenital serovars D and H and Chlamydia muridarum

    by J M Lyons, Jr J I Ito, A S Peña, S A Morré

    Aim: In vitro growth and elementary body (EB) associated cytotoxicity of two Chlamydia trachomatis strains belonging to serovars D and H and C muridarum were compared to identify difference(s) that correlate with virulence variations between these strains in the mouse model of human female genital tract infection, and phenotypic characteristics that could explain human epidemiological data on serovar prevalence and levels of shedding during serovar D and H infection. Methods: Replication cycle kinetics, inclusion characteristics, and EB associated cytotoxicity were assessed in McCoy cell monolayers using culture, light microscopy, and lactate dehydrogenase release. Results: Over 72 hours, more rapid production and release of inclusion forming units (ifu) allowed C muridarum to initiate two replication rounds, resulting in 4–8 times more ifu/input unit of infection than with serovars D and H. Although C muridarum EBs were significantly more cytotoxic to McCoy cell monolayers than serovar D at moderate and high multiplicity of infection ratios (MOI), serovar H EBs were significantly more cytotoxic than C muridarum , even at the lowest MOI tested. Conclusions: These phenotypic differences are consistent with the more invasive course and severe pathological outcome of infection in mice infected with C muridarum , providing an objective basis for questioning the appropriateness of C muridarum as a surrogate for the human biovar of C trachomatis in the murine model of female genital tract infection. The differences seen between the human strains could help explain human epidemiological data relating to differences in prevalence and level of shedding that occurs during infection with oculogenital serovars D and H.


  • Open Access

    Chlamydia trachomatis serovar E isolates from patients with different clinical manifestations have similar courses of infection in a murine model: host factors as major determinants of C trachomatis mediated pathogenesis

    by J M Lyons, Jr J I Ito, S A Morré

    Background: Some investigators have proposed an association between certain Chlamydia trachomatis serovars and the clinical course of infection in humans. A recent study of over 1100 patients with culture confirmed and serotyped C trachomatis urogenital infection detected no such association. Aims: To corroborate these results using a murine model of female genital tract infection. Methods: Various parameters of infection were assessed in mice intravaginally infected with human genital isolates of C trachomatis serovar E from four cases with either a clear symptomatic or asymptomatic clinical course in both the patient and their partner. Results: No differences were seen among the strains in the incidence or duration of infection, polymorphonuclear granulocyte responses, or upper genital tract progression. Conclusions: An investigation to determine the correlation between the clinical manifestations of different isolates of C trachomatis serovar E in humans and certain parameters of microbial pathogenesis in a mouse model failed to reveal an association between the measured parameters and the tendency of serovar E to produce symptomatic versus asymptomatic infections in humans. These findings suggest that differences in the clinical course of infection in humans seen with these strains may be more related to host factors than to genetic variation among strains.